In particular, it has been demonstrated by Li et al. that neoadjuvant lapatinib treatment led to a decrease in the CD44+CD24− population, as well as a reduction in mammosphere formation of samples from breast cancer patient biopsies [122]. This evidence concerns the gene CD44 and breast cancer.